Hornback N B, Omura G, Major F J
Int J Radiat Oncol Biol Phys. 1986 Dec;12(12):2127-30. doi: 10.1016/0360-3016(86)90011-8.
From November 1973 through July 1982, 225 women with Stage I or II uterine sarcoma were entered on a protocol which evaluated the use of doxorubicin in the adjuvant setting. Of these, 157 patients had a minimum follow-up of 2 years. Following complete surgical removal of all known clinical disease, consenting patients were randomized to receive either 60 mg/m2 of doxorubicin every 3 weeks for eight courses or no further therapy. The use of radiation therapy in this protocol was optional, and a review of protocol cases was undertaken to determine progression-free interval, survival rates, and site of first recurrence in the radiation therapy and no radiation therapy groups. In patients with Stage I or II leiomyosarcoma of the uterus, there was no difference in the progression-free interval, absolute two-year survival rate, or site of first recurrence in the two groups. There was no difference in the progression-free interval or absolute survival rates for cases with Stage I and II uterine mixed mesodermal sarcomas in the two treatment groups. However, those who received radiation therapy to the pelvis experienced a statistically significant reduction of recurrences within the radiation treatment field.
从1973年11月至1982年7月，225例I期或II期子宫肉瘤女性患者参与了一项评估阿霉素辅助治疗作用的方案。其中，157例患者至少随访了2年。在所有已知临床疾病均通过手术完全切除后，同意参与的患者被随机分为两组，一组每3周接受一次剂量为60mg/m²的阿霉素，共八个疗程；另一组不再接受进一步治疗。本方案中放射治疗的使用为可选项目，我们对方案病例进行了回顾，以确定无进展生存期、生存率以及放射治疗组和非放射治疗组首次复发的部位。对于I期或II期子宫平滑肌肉瘤患者，两组在无进展生存期、绝对两年生存率或首次复发部位方面均无差异。两个治疗组中I期和II期子宫混合性中胚叶肉瘤病例的无进展生存期或绝对生存率也无差异。然而，接受盆腔放射治疗的患者在放射治疗区域内的复发率在统计学上有显著降低。
